Diagnosis, Treatment, and Survivorship of Lymphoma in the Era of Personalized Medicine
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: 20 January 2026 | Viewed by 107
Special Issue Editor
Special Issue Information
Dear Colleagues,
Lymphoma is a rare hematologic malignancy that is broadly categorized into two main types, Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). More than 80% of patients with HL can be cured with current treatment approaches, yet long-term complications associated with cytotoxic chemotherapy remain an ongoing challenge. Personalized medicine offers the possibility of identifying HL patients that can be cured with less toxic regimens in an effort to minimize adverse effects and improve patient quality of life. Differently, NHLs are a heterogeneous group of lymphomas encompassing varied forms ranging from indolent to aggressive presentations with different outcomes and curability of the disease. With recent advances such as next-generation sequencing (NGS), personalized medicine offers opportunities to diagnose NHL patients earlier, tailor treatment based on genomic or molecular alterations, minimize adverse effects, and detect relapsed disease sooner.
This Special Issue of the Journal of Personalized Medicine aims to highlight the recent developments in personalized approaches to the diagnosis, treatment, and survivorship of lymphoma patients. Articles or comprehensive reviews on the identification and characterization of novel biomarkers for disease diagnosis, therapy selection, and monitoring, as well as those that describe new methods and approaches used for these purposes, are welcome.
Dr. Andrew Ip
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lymphoma
- non-Hodgkin lymphoma
- Hodgkin lymphoma
- personalized medicine
- next-generation sequencing
- early detection
- survivorship
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
